Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy

AIDS

Volumn 27, Issue 7, 2013, Pages 1129-1134

  Fernández Montero, José Vicente ^a   Barreiro, Pablo ^a   Vispo, Eugenia ^a   Labarga, Pablo ^a   Sánchez Parra, Clara ^a   Soriano, Vicente ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cirrhosis; Hepatitis C virus; HIV; Liver fibrosis; Mortality; Transient elastometry

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASCITES; BRAIN DISEASE; CLINICAL ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LIVER STIFFNESS; MALE; MORTALITY; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COINFECTION; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX FACTORS; SURVIVAL ANALYSIS;

EID: 84879120471     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835e063f     Document Type: Article

References (23)

1. Palella F, Baker R, Moorman A, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Def Syndr 2006; 43:27-34.
2. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24:1537-1548.
3. Weber R, Sabin C, Friis-Møller N. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
4. Puoti M, Moioli M, Travi G, Rossotti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis 2012; 32:103-113.
5. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012; 32:138-146.
6. Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402.
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/ lvguidelines/AdultandAdolescentGL.pdf. [Accessed 1 September 2012]
8. Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, et al. Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. J Viral Hepat 2008; 15:165-172.
9. Tuma P, Jarrin I, Del Amo J, Vispo E, Medrano J, Martin-Carbonero L, et al. Survival of HIV-infected patients with compensated liver cirrhosis. AIDS 2010; 24:745-753.
10. Myers R, Fong A, Shaheen A. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28:705-712.
11. Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (Fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49:1083-1089.
12. de Lédinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41:175-179.
13. Kirk G, Astemborski J, Mehta S, Spoler C, Fisher C, Allen D, et al. Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009; 48:963-972.
14. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
15. Vergniol J, Foucher J, Terrebonne E, Bernard PH, le Bail B, Merrouche W, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140:1970-1979.
16. Lindvig K, Mössner B, Pedersen C, Lillevang ST, Christensen PB. Liver stiffness and 30-day mortality in a cohort of patients admitted to hospital. Eur J Clin Invest 2012; 42:146-152.
17. Limketkai B, Mehta S, Sutcliffe C, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308:370-378.
18. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-1353.
19. Bambha K, Pierce C, Cox C, French AL, Tien PC, Sharp GB, et al. Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS 2012; 26:599-607.
20. Merchante N, Rivero-Juárez A, Téllez F, Merino D, José Ríos Villegas M, Márquez-Solero M, et al. Liver stiffness predicts clinical outcome in HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 2012; 56:228-238.
21. Soriano V, Maida I, Nuñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, et al. Long-term follow-up of HIV-infected patients with chronic HCV infection treated with interferon-based therapies. Antivir Ther 2004; 9:987-992.
22. Berenguer J, Alvarez-Pellicer J, Martín P, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with HIV and hepatitis C virus. Hepatology 2009; 50:407-413.
23. Soriano V, Sherman K, Rockstroh J, Dieterich D, Back D, Sulkowski M, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25:2197-2208.